Cannabis: The Effects on Patients With Respiratory Conditions
Price: FREE for members and non-members
Session recorded on May 21, 2020
Speaker: William Silvers, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this podcast, the participant should be able to:
- Describe the spectrum and prevalence of allergic reactions to Cannabis (“Marijuana”)
- Discuss better communication, non-judgmental, between patients and physicians
- Update on diagnosis, management, and benefits/harms of cannabis
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
William Silvers, MD, Speaker
Nothing to disclose
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance